FDA Approves Padcev for Muscle-Invasive Bladder Cancer

TUESDAY, Dec. 2, 2025-- The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy adjuvant treatment for adult...